Regen BioPharma, Inc. (RGBP)
OTCMKTS
· Delayed Price · Currency is USD
0.0009
0.00 (0.00%)
Mar 6, 2026, 1:57 PM EST
Regen BioPharma Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Revenue | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | Upgrade
|
| Revenue Growth (YoY) | 0% | 0% | - | 0.44% | 37.57% | 55.63% | Upgrade
|
| Gross Profit | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | Upgrade
|
| Selling, General & Admin | 0.84 | 0.56 | 0.5 | 0.71 | 0.3 | 0.34 | Upgrade
|
| Research & Development | 0.22 | 0.01 | 0.15 | 0.21 | 0.28 | 0.04 | Upgrade
|
| Operating Expenses | 1.07 | 0.58 | 0.65 | 0.92 | 0.58 | 0.37 | Upgrade
|
| Operating Income | -0.83 | -0.34 | -0.42 | -0.69 | -0.34 | -0.2 | Upgrade
|
| Interest Expense | -0.21 | -0.21 | -0.1 | -0.06 | -0.21 | -0.37 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.69 | -0.73 | -0.15 | 1.9 | 3 | -4.26 | Upgrade
|
| EBT Excluding Unusual Items | -1.73 | -1.27 | -0.67 | 1.16 | 2.45 | -4.83 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.03 | -1.16 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -0.8 | Upgrade
|
| Other Unusual Items | - | - | - | 0 | -0.03 | 0.02 | Upgrade
|
| Pretax Income | -1.73 | -1.27 | -0.67 | 1.16 | 2.44 | -6.77 | Upgrade
|
| Net Income | -1.73 | -1.27 | -0.67 | 1.16 | 2.44 | -6.77 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 0.13 | 0.22 | - | Upgrade
|
| Net Income to Common | -1.73 | -1.27 | -0.67 | 1.02 | 2.23 | -6.77 | Upgrade
|
| Net Income Growth | - | - | - | -52.67% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 47 | 47 | 16 | 14 | 13 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 47 | 16 | 14 | 13 | 8 | Upgrade
|
| Shares Change (YoY) | 536.19% | 186.14% | 16.21% | 12.79% | 56.19% | 113.61% | Upgrade
|
| EPS (Basic) | -0.04 | -0.03 | -0.04 | 0.07 | 0.18 | -0.84 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.03 | -0.04 | 0.07 | 0.18 | -0.84 | Upgrade
|
| EPS Growth | - | - | - | -59.25% | - | - | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -350.35% | -143.11% | -176.37% | -290.39% | -144.20% | -117.28% | Upgrade
|
| Profit Margin | -730.03% | -538.76% | -282.49% | 432.66% | 945.59% | -3951.79% | Upgrade
|
| EBIT | -0.83 | -0.34 | -0.42 | -0.69 | -0.34 | -0.2 | Upgrade
|
| EBIT Margin | - | -143.11% | -176.37% | -290.39% | -144.19% | -117.28% | Upgrade
|
| Revenue as Reported | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.